乙肝相关性肝癌患者口服抗病毒药物管理

Status Quo and Prospect of Oral Administration of Antivirus Drug Management in Hepatitis B Related Patients

肝癌是乙型肝炎病毒感染后演变的一个重要临床结局,其中抗病毒治疗正是延缓这一过程的关键举措。长效干扰素由于不良反应相对口服抗病毒药物严重及皮下注射的给药途径,致使口服抗病毒治疗在临床上应用更加广泛。但由于需要长期坚持服药,定期复查,监测其耐药性,给患者生活带来一定影响,导致患者服药依从性不佳。影响患者规范用药除了患者自身认知、依从性不足以外,还有很多其他外在因素。越来越多文章指出全面、连续、一体化治疗的重要性。文章为患者、家属、医务人员及社会其他人群呈现影响口服抗病毒药物管理的多方面原因,改善口服抗病毒药物的管理。

Liver cancer is a very important clinical result after been infected by hepatitis B virus.At present,antiviral therapy is a kind of measure to delay this process.Compared with oral antiviral drugs,pegylated interferon's side effect is worse and it's administration route,subcutaneous injection,is more complex for patients.Therefore,the application of oral antivirals is more widely in clinic.But oral antivirals need long-term medication,regular follow-ups,and drug resistance monitor.All these factors would affect the drug therapy compliance.Apart from patients'poor cognition and compliances,there are other external factors that would affect patients'standard medication.More and more articles point that comprehensive,continuous,integrative therapy is very important.The purpose of this article is to present various factors in affecting oral antivirals management for the patients,families,medical staff and the rest of society.